Stay updated on SAGE-217 in Essential Tremor Clinical Trial
Sign up to get notified when there's something new on the SAGE-217 in Essential Tremor Clinical Trial page.

Latest updates to the SAGE-217 in Essential Tremor Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedLocations section added listing study sites by state (AL, AR, CA, CO, FL, GA, IL, MO, NC, OH, TN, TX). The page revision updated from v3.3.2 to v3.3.3.SummaryDifference1%

- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedThe page footer now shows Revision: v3.3.2, replacing the previous v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check52 days agoChange DetectedThe notice about lapse in government funding and NIH operating status has been removed from the page, and this does not affect the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check66 days agoChange DetectedThe two screenshots show minor visual/layout updates with no changes to fundamental study details or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check95 days agoChange DetectedMajor update: adds a government funding and operating status notice and marks the page as revision v3.2.0, replacing v3.1.0.SummaryDifference2%

- Check102 days agoChange DetectedAdded a new revision label v3.1.0 and removed several drug-safety and pharmaceutical topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) along with an older revision v3.0.2. The update shifts the page toward a release/versioning focus while narrowing drug-related content.SummaryDifference0.2%

Stay in the know with updates to SAGE-217 in Essential Tremor Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAGE-217 in Essential Tremor Clinical Trial page.